Real-world experience of ozanimod in adults with multiple sclerosis
Ozanimod was well-tolerated with good treatment persistence, a favorable safety profile, and reductions in clinical and radiographic disease.
Authors
- Jessica Cooperrider (ORCID: https://orcid.org/0000-0003-0593-9626)
- Carrie M. Hersh (ORCID: https://orcid.org/0000-0002-5716-5645)
- Jennifer Reardon
- Jeffrey Lambe (ORCID: https://orcid.org/0000-0002-3306-0988)
- Andrew Thorpe
- Devon Conway
- Burhan Chaudry
- Mengke Du
- Michelle Chu
Institutions
- Cleveland Clinic (US)
- Bristol-Myers Squibb (Germany) (DE)
- Lou Ruvo Brain Institute (US)
- Neurology, Inc (US)
- Touro University Nevada (US)
Publication Details
- Journal
- Neurodegenerative Disease Management
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1080/17582024.2026.2622078
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00